$COCP News

Cocrystal Pharma’s new CEO hopes to crack the norovirus code

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

COCP: $5 Million Private Placement with OPKO Health

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

COCP: Presentation Highlights CDI-988

Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Cocrystal Pharma Features Mechanism Of Action And Clinical Advancement Of Oral Protease Inhibitor CDI-988 In Oral Presentation At 39th ICAR 2026

Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities

COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention

Why Cocrystal Pharma Shares Are Cooling Off Monday?

We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive